News & InsightsPharmacy 2030 Hub
The future of pharmacy isn’t something to watch. It’s something to build. Our Pharmacy 2030 Hub brings together market intelligence, expert perspectives, and emerging trends to help organizations understand what’s next—and act before it arrives.
Pharmaceutical Tariffs Are Here. Will Drug Prices Actually Go Up?
A new tiered tariff framework targets brand-name drugs, but most major manufacturers secured 0% rates—here's what plan sponsors should watch.
pharmaceutical-tariffs-are-here-will-drug-prices-actually-go-up
insights
regulatory-shifts
access-affordability
Rx Insights from June '26
This month's Rx Insights covers UTEBZI, the first oral carbapenem antibiotic approved for complicated urinary tract infections, plus its safety data.
rx-insights-from-june-26
insights
new-emerging-rx-therapies
clinical-strategy
Your PBM Tells You What Changed. Who's Telling You Why?
Annual PBM formulary notices rarely explain the financial reasoning behind changes, plus a look at Medicare's new GLP-1 Bridge program launching July 2026.
your-pbm-tells-you-what-changed-whos-telling-you-why
insights
pharmacy-strategy
rebate-financial-strategy
Waiting for Your PBM to Tell You What Changed Isn't a Strategy
Passive formulary management leaves plans exposed to hidden costs like leakage and pricey generics—here's how to demand real financial analysis from your PBM.
waiting-for-your-pbm-to-tell-you-what-changed-isnt-a-strategy
insights
pharmacy-strategy
rebate-financial-strategy
PBM Reform Is Exposing the Limits of Legacy Pharmacy Strategy for Payers
As transparency rules tighten pharmacy benefit oversight, legacy PBM strategies are struggling to hold up—here are five priorities for payers to act on now.
pbm-reform-is-exposing-the-limits-of-legacy-pharmacy-strategy-for-payers
insights
regulatory-shifts
pharmacy-strategy
Rx Insights from February '26
A review of four newly approved therapies for presbyopia, atopic dermatitis, bipolar disorder and schizophrenia, and arginase 1 deficiency.
rx-insights-from-february-26
insights
new-emerging-rx-therapies
clinical-strategy
Pharmacy Benefits Transparency Isn't the Future. It's the Foundation.
Expion Health explains how rising regulatory transparency requirements around pharmacy rebates align with the transparency the company has built its foundation on.
pharmacy-benefits-transparency-isnt-the-future-its-the-foundation
insights
regulatory-shifts
rebate-financial-strategy
RX Insights from December '25
A review of nine newly approved therapies spanning oncology, rare genetic disease, infectious disease, respiratory disease, and cardiology.
rx-insights-from-december-25
insights
new-emerging-rx-therapies
clinical-strategy
Cigna's Plan to Shift from Drug Rebates: What it Could Mean for Pharmacy Strategy — and a Call to Action for Smarter Pharmacy Strategy
Cigna's move away from drug rebates signals a bigger shift in pharmacy economics — Expion Health explains why transparency and ExpionIQ matter now.
cignas-plan-to-shift-from-drug-rebates-what-it-could-mean-for-pharmacy-strategy-and-a-call-to-action-for-smarter-pharmacy-strategy
insights
rebate-financial-strategy
market-trends
Rx Insights from September '25
September's Rx Insights covers nine newly approved therapies, from WAYRILZ to PALSONIFY, with indications, dosing, and clinical trial data.
rx-insights-from-september-25
insights
new-emerging-rx-therapies
clinical-strategy
Harnessing Transparency and Control: Key Takeaways from the HCAA Executive Forum from Expion Health
Key takeaways from the HCAA Executive Forum on why TPAs must embrace transparency and technology like ExpionIQ to act as fiduciary-like partners.
harnessing-transparency-and-control-key-takeaways-from-the-hcaa-executive-forum-from-expion-health
insights
regulatory-shifts
technology-intelligence
Expion Health and Mark Cuban Cost Plus Drug Company, PBC Forge Innovative Collaboration to Enhance Pharmacy Cost Management
Expion Health partners with Mark Cuban Cost Plus Drug Company to integrate transparent, lower-cost specialty drug pricing into its Specialty Navigator tool.
expion-health-and-mark-cuban-cost-plus-drug-company-pbc-forge-innovative-collaboration-to-enhance-pharmacy-cost-management
news
access-affordability
rebate-financial-strategy
Blue Shield of California Pharmacy Shake-Up: 3 Disaggregation Considerations for Health Plans
Blue Shield of California's move to multiple specialized PBM partners raises questions for health plans on strategic alignment, expertise, and transparency.
blue-shield-of-california-pharmacy-shake-up-3-disaggregation-considerations-for-health-plans
insights
pharmacy-strategy
market-trends
The Impact of Humira Biosimilars: 5 Factors That Will Reduce Payer Costs
As Humira biosimilars launch in 2023, competition is expected to lower payer costs — here are 5 factors driving that shift, from rebates to formulary positioning.
the-impact-of-humira-biosimilars-5-factors-that-will-reduce-payer-costs
insights
new-emerging-rx-therapies
rebate-financial-strategy
Build pharmacy forward from your inbox
Get the insights shaping what’s next in prescription economics, market pressure and pharmacy strategy.
Move beyond the pharmacy
black box
See how Expion helps organizations build pharmacy strategies with more visibility, flexibility and control from the start.